share_log

Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer

Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer

Deciphera抗癌藥物超越輝瑞在胃腸道癌症安全方面的地位
Benzinga Real-time News ·  2022/08/11 09:46
  • The Journal of Clinical Oncology has published results from Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) INTRIGUE Phase 3 study of Qinlock (ripretinib) for advanced gastrointestinal stromal tumor (GIST) previously treated with Novartis AG's (NYSE:NVS) Gleevec/Glivec (imatinib). 
  • Although Qinlock did not offer a statistically significant improvement in progression-free survival (PFS) compared to sunitinib, the drug showed meaningful clinical activity with fewer Grade 3/4 treatment-emergent adverse events and improved tolerability.
  • In addition, Qinlock had a more favorable safety profile than Pfizer Inc's (NYSE:PFE) Sutent (sunitinib), with fewer Grade 3/4 adverse events.
  • Patients in the Qinlock arm reported less deterioration in role functioning and better outcomes than sunitinib.
  • In patients with a KIT exon 11 primary mutations, ripretinib demonstrated a median PFS (mPFS) of 8.3 months compared to 7.0 months for the sunitinib arm. 
  • In the intention-to-treat (ITT) population, ripretinib demonstrated an mPFS of 8.0 months vs. 8.3 months.
  • In patients with a KIT exon 11 primary mutations, ripretinib demonstrated an objective response rate of 23.9% vs. 14.6%, and 21.7% vs. 17.6% in the ITT populations.
  • The FDA has approved Qinlock for advanced GIST patients who have received prior treatment with three or more kinase inhibitors.
  • Price Action: DCPH shares traded 3.66% lower at $16.57 on the last check Thursday.
  • 《臨牀腫瘤學雜誌》發表了來自Deciphera製藥公司納斯達克：DCPH關於秦洛克(利普替尼)治療晚期胃腸道間質瘤的有趣的3期研究諾華製藥(紐約證券交易所代碼：NVS)Gleevec/Glivec(伊馬替尼)。
  • 儘管與舒尼替尼相比，秦洛克在無進展存活率(PFS)方面沒有提供統計上的顯著改善，但該藥物顯示出有意義的臨牀活性，3/4級治療--緊急不良事件和耐受性得到改善。
  • 此外，秦鎖的安全狀況比輝瑞(紐約證券交易所股票代碼：PFE)舒坦(孫尼替尼)，3/4級不良事件較少。
  • 秦鎖臂的患者報告説，與舒尼替尼相比，角色功能惡化較少，結果更好。
  • 在KIT外顯子11原發突變的患者中，利普替尼的中位PFS(MPFS)為8.3個月，而舒尼替尼組為7.0個月。
  • 在意向治療(ITT)人羣中，利普替尼的MPFS為8.0個月，而不是8.3個月。
  • 在KIT外顯子11原發突變的患者中，利普替尼在ITT人羣中的客觀應答率分別為23.9%和21.7%，分別為14.6%和17.6%。
  • FDA已經批准Qinlock用於先前接受過三種或更多激酶抑制劑治療的晚期GIST患者。
  • 價格行動：在週四的最後一次檢查中，DCPH的股價下跌了3.66%，至16.57美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論